Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition
The Motley Fool
by newsfeedback@fool.com (Jonathan Ponciano)February 17, 2026
Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.
Verticals
financeinvesting
Originally published on The Motley Fool on 2/17/2026